Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Veronate (Inhibitex).

David Kaufman1

  • 1University of Virginia Health System, Department of Pediatrics, Charlottesville 22908, USA. DAK4R@virginia.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|February 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study.

Journal of translational medicine·2026
Same author

Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior.

Allergy and asthma proceedings·2026
Same author

Unmasking the underlying cause: A rash with deeper implications.

Allergy and asthma proceedings·2025
Same author

Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study.

Journal of translational medicine·2025
Same author

Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.

Brain, behavior, & immunity - health·2025
Same author

Low Dose Rapamycin Alleviates Clinical Symptoms of Fatigue and PEM in ME/CFS Patients via Improvement of Autophagy.

Research square·2025

Veronate is an antibody immunotherapy being developed to prevent infections in premature infants. Ongoing Phase III trials are evaluating its effectiveness against Staphylococcus and Candida species.

Area of Science:

  • Neonatal immunology
  • Infectious disease prevention
  • Antibody-based therapeutics

Background:

  • Very-low-birth-weight infants are highly susceptible to bacterial and fungal infections.
  • Staphylococcus epidermidis, Staphylococcus aureus, and Candida species are common pathogens causing severe infections in this vulnerable population.
  • Effective preventative strategies are crucial to reduce infant morbidity and mortality.

Purpose of the Study:

  • To evaluate the efficacy of Veronate, an antibody-based immunotherapy, for the prevention of infections caused by Staphylococcus epidermidis, Staphylococcus aureus, and Candida.
  • To assess the safety and tolerability of Veronate in very-low-birth-weight infants.

Main Methods:

  • Development of Veronate, a novel antibody-based immunotherapy.

Related Experiment Videos

  • Ongoing Phase III clinical trials to assess Veronate's efficacy and safety.
  • Targeting common pathogens including Staphylococcus epidermidis, Staphylococcus aureus, and Candida.

    • Main Results:

    • Phase III clinical trials are currently underway, results are pending.
    • The study aims to determine the preventative potential of Veronate.

    Conclusions:

    • Veronate holds promise as a novel preventative immunotherapy for vulnerable infants.
    • Further results from ongoing clinical trials are necessary to confirm its clinical utility.